BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement

06-Mar-2008

BIKAM and Dalton medicinal chemistry, have jointly announced an exclusive worldwide collaboration and agreement to discover and develop new therapeutics for unmet needs in ophthalmology.

Dalton Medicinal Chemistry will utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their cutting edge battery of biological assays and delivery methodologies.

David Garvey, VP, Chemistry at BIKAM commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery and development of new entities for treating eye diseases. Their expertise, together with our propriety and leading position will quickly deliver important new medicines."

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance